Skip to main content
Top
Published in: Medical Oncology 2/2015

01-02-2015 | Original Paper

An Anticancer Drug Unit for the whole provincial oncologic network of Piacenza: improving safety and savings

Authors: Patrizia Mordenti, Stefano Vecchia, Enrico Damonti, Alessandra Riva, Monica Muroni, Maria Rosa Cordani, Gabriele Cremona, Luigi Cavanna

Published in: Medical Oncology | Issue 2/2015

Login to get access

Abstract

In recent years, the expenditure for cancer care is increased largely due to the increase in cancer prevalence, demographic changes and incorporation into clinical practice of new and expensive drugs. For these reasons, solutions to contain costs are necessaries. The drugs-related expenditure is proportionally higher in oncology than in other medical specialties and overcomes staffing costs for outpatient care. The introduction of additional measures to contain and reduce expenditures such as waste reduction and human resources optimization is highly desirable. On April 2013, we started a day-to-day monitoring of the consumption of drugs and developed an internal protocol for waste minimization, consisting of five measures. A computerized research through Medline, Cancerlit and Embase was performed, applying the words drug waste, cost-containment, Anticancer Drug Unit and stability instructions. Articles and abstracts were also identified by back-referencing from other relevant papers. Selected for the present review were papers published in English without limit of year. The day-to-day monitoring of the consumption of drugs and the internal protocol for waste minimization were able to achieve a saving of €15,700 every month. The projection of an annual cost-saving result of €188.00 corresponds to a recovery of 4 % on the spending for oncologic drugs. Our data show that in a proper structure working according to the standards of quality, safety and sterility, preserving and reusing the drug waste within the limits imposed by the datasheets, it is possible to achieve a cost-containment policy and produce durable benefits.
Literature
1.
go back to reference Berry SR, Bell CM, Ubel PA, Evans WK, Nadler E, Strevel EL, et al. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. J Clin Oncol. 2010;28:4149–53.PubMedCrossRef Berry SR, Bell CM, Ubel PA, Evans WK, Nadler E, Strevel EL, et al. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. J Clin Oncol. 2010;28:4149–53.PubMedCrossRef
2.
3.
go back to reference Hoffman JM, Shah ND, Vermeulen LC, Doloresco F, Martin PK, Blake S, et al. Projecting future drug expenditure–2009. Am J Health Syst Pharm. 2009;166:237–57.CrossRef Hoffman JM, Shah ND, Vermeulen LC, Doloresco F, Martin PK, Blake S, et al. Projecting future drug expenditure–2009. Am J Health Syst Pharm. 2009;166:237–57.CrossRef
4.
go back to reference Bach PB. Costs of cancer care: a view from the centers for medicare and medical services. J Clin Oncol. 2007;25:187–90.PubMedCrossRef Bach PB. Costs of cancer care: a view from the centers for medicare and medical services. J Clin Oncol. 2007;25:187–90.PubMedCrossRef
5.
6.
go back to reference Cheema PK, Gavura S, Migus M, Godman L, Yeung L, Trudeau ME. International variability in the reimbursement of cancer drugs by publically funded drug programs. Curr Oncol. 2012;19:e165–76.PubMedCentralPubMedCrossRef Cheema PK, Gavura S, Migus M, Godman L, Yeung L, Trudeau ME. International variability in the reimbursement of cancer drugs by publically funded drug programs. Curr Oncol. 2012;19:e165–76.PubMedCentralPubMedCrossRef
7.
go back to reference Nava-Ocampo AA, Alarcón-Almanza JM, Moyao-García D, Ramírez-Mora JC, Salmerón J. Undocumented drug utilization and drug waste increase costs of pediatric anesthesia care. Fundam Clin Pharmacol. 2004;18:107–12.PubMedCrossRef Nava-Ocampo AA, Alarcón-Almanza JM, Moyao-García D, Ramírez-Mora JC, Salmerón J. Undocumented drug utilization and drug waste increase costs of pediatric anesthesia care. Fundam Clin Pharmacol. 2004;18:107–12.PubMedCrossRef
8.
go back to reference Diehl LD, Goo ED, Sumiye L, Ferrell R. Reducing waste of intravenous solutions. Am J Hosp Pharm. 1992;49:106–8.PubMed Diehl LD, Goo ED, Sumiye L, Ferrell R. Reducing waste of intravenous solutions. Am J Hosp Pharm. 1992;49:106–8.PubMed
9.
go back to reference Favier M, Fliche E, Bressolle F. Economic benefit of a centralized reconstitution unit of cytotoxic drugs in isolator. J Oncol Pharm Pract. 1996;2:182–5.CrossRef Favier M, Fliche E, Bressolle F. Economic benefit of a centralized reconstitution unit of cytotoxic drugs in isolator. J Oncol Pharm Pract. 1996;2:182–5.CrossRef
10.
go back to reference Gillerman RG, Browning RA. Drug use inefficiency: a hidden source of wasted health care dollars. Anesth Analg. 2000;91:921–4.PubMedCrossRef Gillerman RG, Browning RA. Drug use inefficiency: a hidden source of wasted health care dollars. Anesth Analg. 2000;91:921–4.PubMedCrossRef
11.
go back to reference Chaudhary K, Garg R, Bhalotra AR, Anand R, Girdhar K. Anesthetic drug wastage in the operation room: a cause concern. J Anesthesiol Clin Pharmacol. 2012;28:56–61.CrossRef Chaudhary K, Garg R, Bhalotra AR, Anand R, Girdhar K. Anesthetic drug wastage in the operation room: a cause concern. J Anesthesiol Clin Pharmacol. 2012;28:56–61.CrossRef
12.
go back to reference AAVV, Gruppo di Lavoro in Oncologia SIFO Lombardia. Compendio farmacologico e tecnico-farmaceutico alle linee guida SIFO in Oncologia. Schede monografiche di tecnica farmaceutica. Il pensiero Scientifico Editore; 2013. p.173–257. AAVV, Gruppo di Lavoro in Oncologia SIFO Lombardia. Compendio farmacologico e tecnico-farmaceutico alle linee guida SIFO in Oncologia. Schede monografiche di tecnica farmaceutica. Il pensiero Scientifico Editore; 2013. p.173–257.
13.
go back to reference Trissel LA. Handbook on injectable drugs. American Society of Health-System Pharmacists, Inc., 15th ed. 2009. Trissel LA. Handbook on injectable drugs. American Society of Health-System Pharmacists, Inc., 15th ed. 2009.
14.
go back to reference Field K, Zelenko A, Kosmider S, Court K, Ng LL, Hibbert M, et al. Dose rounding of chemotherapy in colorectal cancer: an analysis of clinician attitudes and the potential impact on treatment costs. Asia Pac J Clin Oncol. 2010;6:203–9.PubMedCrossRef Field K, Zelenko A, Kosmider S, Court K, Ng LL, Hibbert M, et al. Dose rounding of chemotherapy in colorectal cancer: an analysis of clinician attitudes and the potential impact on treatment costs. Asia Pac J Clin Oncol. 2010;6:203–9.PubMedCrossRef
15.
go back to reference Dooley MJ, Singh S, Michael M. Implications of dose rounding of chemotherapy to the nearest vial size. Support Care Cancer. 2004;12:653–6.PubMedCrossRef Dooley MJ, Singh S, Michael M. Implications of dose rounding of chemotherapy to the nearest vial size. Support Care Cancer. 2004;12:653–6.PubMedCrossRef
19.
go back to reference Ministero del Lavoro della Salute e delle Politiche Sociali, Istituto Superiore Sanità. Norme di buona preparazione dei medicinali in farmacia. Aspetti microbiologici dei preparati. In: Farmacopea Ufficiale della repubblica Italiana, 12th edn. Libreria dello Stato; 2008. p. 1423–25. Ministero del Lavoro della Salute e delle Politiche Sociali, Istituto Superiore Sanità. Norme di buona preparazione dei medicinali in farmacia. Aspetti microbiologici dei preparati. In: Farmacopea Ufficiale della repubblica Italiana, 12th edn. Libreria dello Stato; 2008. p. 1423–25.
21.
go back to reference Fasola G, Aprile G, Marini L, Follador A, Mansutti M, Miscoria M. Drug waste minimization as an effective strategy of cost-containment in oncology. BMC Health Serv Res. 2014;14:57.PubMedCentralPubMedCrossRef Fasola G, Aprile G, Marini L, Follador A, Mansutti M, Miscoria M. Drug waste minimization as an effective strategy of cost-containment in oncology. BMC Health Serv Res. 2014;14:57.PubMedCentralPubMedCrossRef
Metadata
Title
An Anticancer Drug Unit for the whole provincial oncologic network of Piacenza: improving safety and savings
Authors
Patrizia Mordenti
Stefano Vecchia
Enrico Damonti
Alessandra Riva
Monica Muroni
Maria Rosa Cordani
Gabriele Cremona
Luigi Cavanna
Publication date
01-02-2015
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2015
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0457-y

Other articles of this Issue 2/2015

Medical Oncology 2/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.